Literature DB >> 23227892

Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.

Makoto Shimanishi1, Kazuhiro Ogi, Yohei Sogabe, Takeshi Kaneko, Hironari Dehari, Akihiro Miyazaki, Hiroyoshi Hiratsuka.   

Abstract

BACKGROUND: During tumor development, cells are exposed to a hypoxic microenvironment. Tumor hypoxia also has a profound influence on the sensitivity of cancer chemotherapy. The objective of this study was to investigate the mechanism of cisplatin (CDDP) resistance of oral squamous cell carcinoma (OSCC) cells under hypoxia by analyzing gene expression profiles to identify key genes and factors involved.
METHODS: Cell viability was measured following culture of the cells in the presence or absence of CDDP, under normoxic or hypoxic conditions, using a CCK-8 assay. Analysis of the expression of HIF target genes in hypoxia-treated cells was performed using an HIF-regulated cDNA plate array. Changes in the mRNA expression of selected HIF target genes were analyzed using RT-PCR, and changes in the protein levels of these genes were analyzed by Western blotting. Tumor cell apoptosis was assessed by flow cytometry.
RESULTS: The OSCC cell lines responded differently to CDDP under normoxic and hypoxic conditions. The expression of glucose transporter protein-1 (GLUT-1) was up-regulated in human squamous cell carcinoma of mouth (HSC-2) cells under hypoxia. Furthermore, there was little correlation between the cisplatin sensitivity of human squamous cell carcinoma of tongue (SAS) in normoxia and hypoxia. After GLUT-1 knockdown, CDDP treatment resulted in increased rates of apoptosis under hypoxia as compared with normoxia in cell lines HSC-2, Ca9-22, and SAS (P = 0.025).
CONCLUSION: The results of this study suggest that knockdown of GLUT-1 inhibits sensitization of oral squamous cells to CDDP during hypoxia in HSC-2, Ca9-22, and SAS cells.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23227892     DOI: 10.1111/jop.12028

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  15 in total

1.  Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study.

Authors:  Ying-Ying Xu; Ting-Ting Wu; Shui-Hong Zhou; Yang-Yang Bao; Qin-Ying Wang; Jun Fan; Ya-Ping Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  GLUT1 participates in tamoxifen resistance in breast cancer cells through autophagy regulation.

Authors:  Mengqi Sun; Shu Zhao; Yuchen Duan; Yumeng Ma; Yicheng Wang; Hongfei Ji; Qingyuan Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-05       Impact factor: 3.000

3.  Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.

Authors:  Katarzyna Starska; Ewa Forma; Paweł Jóźwiak; Magdalena Bryś; Iwona Lewy-Trenda; Ewa Brzezińska-Błaszczyk; Anna Krześlak
Journal:  Tumour Biol       Date:  2014-11-21

4.  Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma.

Authors:  Lin Feng; Ling-Ling E; Michail Michailovich Soloveiv; Dong-Sheng Wang; B O Zhang; Yu Wan Dong; Hong-Chen Liu
Journal:  Oncol Lett       Date:  2015-02-03       Impact factor: 2.967

5.  Expression and significance of glucose transporter-1, P-glycoprotein, multidrug resistance-associated protein and glutathione S-transferase-π in laryngeal carcinoma.

Authors:  Zhong-Ping Mao; Li-Jun Zhao; Shui-Hong Zhou; Meng-Qin Liu; Wei-Feng Tan; Hong-Tian Yao
Journal:  Oncol Lett       Date:  2014-12-01       Impact factor: 2.967

6.  Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.

Authors:  Andreas Koch; Sven Arke Lang; Peter Johannes Wild; Susanne Gantner; Abdo Mahli; Gerrit Spanier; Mark Berneburg; Martina Müller; Anja Katrin Bosserhoff; Claus Hellerbrand
Journal:  Oncotarget       Date:  2015-10-20

7.  Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.

Authors:  Xin Ren; Hao Liu; Mingjie Zhang; Mengjun Wang; Shiyin Ma
Journal:  Mol Med Rep       Date:  2016-07-27       Impact factor: 2.952

8.  Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.

Authors:  Makoto Yamamoto; Tetsuya Tsujikawa; Yuko Fujita; Yoko Chino; Tetsuji Kurokawa; Yasushi Kiyono; Hidehiko Okazawa; Yoshio Yoshida
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

9.  Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo.

Authors:  Xing-Mei Luo; Bin Xu; Min-Li Zhou; Yang-Yang Bao; Shui-Hong Zhou; Jun Fan; Zhong-Jie Lu
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

Review 10.  Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma.

Authors:  Alexander W Eckert; Claudia Wickenhauser; Paul C Salins; Matthias Kappler; Juergen Bukur; Barbara Seliger
Journal:  J Transl Med       Date:  2016-04-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.